Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.
Allen JA, Lin J, Basta I, Dysgaard T, Eggers C, Guptill JT, Gwathmey KG, Hewamadduma C, Hofman E, Hussain YM, Kuwabara S, Le Masson G, Leypoldt F, Chang T, Lipowska M, Lowe M, Lauria G, Querol L, Simu MA, Suresh N, Tse A, Ulrichts P, Van Hoorick B, Yamasaki R, Lewis RA, van Doorn PA; ADHERE Study Group. Allen JA, et al. Among authors: tse a. Lancet Neurol. 2024 Oct;23(10):1013-1024. doi: 10.1016/S1474-4422(24)00309-0. Lancet Neurol. 2024. PMID: 39304241 Clinical Trial.
Rosette-forming multicentric B-cell lymphoma in a giant panda.
Tse ACN, Brackman CJ, Yuen CPM, Perkins CM, Martelli P, Tse MPY. Tse ACN, et al. J Vet Diagn Invest. 2024 Nov;36(6):945-948. doi: 10.1177/10406387241267887. Epub 2024 Sep 6. J Vet Diagn Invest. 2024. PMID: 39243117
A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma.
Gong J, Guo Y, Zhang Y, Ba Y, Chen T, Li W, Zhou C, Wang M, Yang H, Zhou Y, Cai Q, Wang Z, Huang G, Zhang W, Su R, Cai Z, Yue Z, Dou J, Li P, Wu R, Tse AN, Shen L. Gong J, et al. Among authors: tse an. Target Oncol. 2024 Sep;19(5):723-733. doi: 10.1007/s11523-024-01091-8. Epub 2024 Sep 4. Target Oncol. 2024. PMID: 39231855 Clinical Trial.
Simulation-driven design of stabilized SARS-CoV-2 spike S2 immunogens.
Nuqui X, Casalino L, Zhou L, Shehata M, Wang A, Tse AL, Ojha AA, Kearns FL, Rosenfeld MA, Miller EH, Acreman CM, Ahn SH, Chandran K, McLellan JS, Amaro RE. Nuqui X, et al. Among authors: tse al. Nat Commun. 2024 Aug 27;15(1):7370. doi: 10.1038/s41467-024-50976-9. Nat Commun. 2024. PMID: 39191724 Free PMC article.
Design and Development of a Multimodal Digital Intervention (SHIFT App) to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant (HSCT) Survivors.
Newcomb R, Traeger L, Jones B, Reynolds M, Tse A, Reese JB, Dizon D, Bober SL, Greer JA, Vanderklish J, Pensak N, DeFilipp Z, Chen YB, Temel JS, El-Jawahri A. Newcomb R, et al. Among authors: tse a. Transplant Cell Ther. 2024 Nov;30(11):1106.e1-1106.e13. doi: 10.1016/j.jtct.2024.08.012. Epub 2024 Aug 23. Transplant Cell Ther. 2024. PMID: 39181537
Distinct pathway for evolution of enhanced receptor binding and cell entry in SARS-like bat coronaviruses.
Tse AL, Acreman CM, Ricardo-Lax I, Berrigan J, Lasso G, Balogun T, Kearns FL, Casalino L, McClain GL, Chandran AM, Lemeunier C, Amaro RE, Rice CM, Jangra RK, McLellan JS, Chandran K, Miller EH. Tse AL, et al. bioRxiv [Preprint]. 2024 Jul 13:2024.06.24.600393. doi: 10.1101/2024.06.24.600393. bioRxiv. 2024. PMID: 38979151 Free PMC article. Preprint.
433 results